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Background: Headache disorders are both common and burdensome but, given the many people affected, provision
of health care to all is challenging. Structured headache services based in primary care are the most efficient, equitable
and cost-effective solution but place responsibility for managing most patients on health-care providers with limited
training in headache care. The development of practical management aids for primary care is therefore a purpose of
the Global Campaign against Headache. This manuscript presents an outcome measure, the Headache Under-Response
to Treatment (HURT) questionnaire, describing its purpose, development, psychometric evaluation and assessment for
clinical utility. The objective was a simple-to-use instrument that would both assess outcome and provide guidance to
improving outcome, having utility across the range of headache disorders, across clinical settings and across countries
and cultures.
Methods: After literature review, an expert consensus group drawn from all six world regions formulated
HURT through item development and item reduction using item-response theory. Using the American
Migraine Prevalence and Prevention Study’s general-population respondent panel, two mailed surveys
assessed the psychometric properties of HURT, comparing it with other instruments as external validators.
Reliability was assessed in patients in two culturally-contrasting clinical settings: headache specialist centres
in Europe (n = 159) and primary-care centres in Saudi Arabia (n = 40). Clinical utility was assessed in similar
settings (Europe n = 201; Saudi Arabia n = 342).
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Results: The final instrument, an 8-item self-administered questionnaire, addressed headache frequency,
disability, medication use and effect, patients’ perceptions of headache “control” and their understanding
of their diagnoses. Psychometric evaluation revealed a two-factor model (headache frequency, disability
and medication use; and medication efficacy and headache control), with scale properties apparently
stable across disorders and correlating well and in the expected directions with external validators. The
literature review found few instruments linking assessment to clinical advice or suggested actions: HURT
appeared to fill this gap. In European specialist care, it showed utility as an outcome measure across
headache disorders. In Saudi Arabian primary care, HURT (translated into Arabic) was reliable and
responsive to clinical change.
Conclusions: With demonstrated validity and clinical utility across disorders, cultures and settings, HURT is
available for clinical and research purposes.
Keywords: Headache disorders, Migraine, Tension-type headache, Cluster headache, Medication-overuse
headache, Management, Treatment planning, Treatment optimization, Acute treatment, Preventative
treatment, Treatment satisfaction, Assessment, Burden, Instruments, Outcome measures, HURT
questionnaire, Follow-up, Primary care, Global campaign against headache,Background
Headache disorders are very common, affecting half or
more of all adults and many children worldwide [1], and
they are highly burdensome [2–8]. The World Health
Organization (WHO) recognised them nearly 20 years
ago as a global public-health priority [9]. Among them,
migraine and tension-type headache (TTH) are often
lifelong illnesses. Medication-overuse headache (MOH),
usually a complication of migraine or TTH caused by
mistreatment of one or the other, is highly frequent,
often present daily or almost so. These three headache
disorders are the substantial contributors to public ill
health, although there are many others [10]. They cause
pain, hinder work, damage family and social relation-
ships and impoverish quality of life (QoL).
Headache disorders are largely treatable [11], and they
demand treatment not only because it is inhumane to ig-
nore these burdens of ill health. The high levels of dis-
ability associated with headache [2–8] lead to very large
productivity losses, so that these disorders are very
costly in a financial sense [12, 13]. Although the eco-
nomic consequences of improving headache care are not
well studied empirically [14], health services that make
the effective remedies more widely available would very
probably be cost saving in most economies [12, 15].
Treatment of headache is therefore demanded also be-
cause it is economically sensible.
Nevertheless, given the very large numbers of people
affected, adequate provision of health care to everyone
for whom self-care is insufficient – perhaps 50% of those
with a headache disorder [16] – is highly challenging.
Structured headache services, with their basis in
primary care and supported by educational initiatives,
are the most efficient, equitable and cost-effective
solution [12]. Such services place responsibility formanaging most people with headache on health-care
providers who lack special expertise in headache man-
agement [16]. This is not in itself problematic: medical
management of headache disorders, for the great ma-
jority of people affected by them, requires no specialist
expertise or investigations but only the diagnostic and
management skills that are available to all physicians
and many other health-care providers in primary care
[12, 16]. On the other hand, non-specialists throughout
the world may have received limited training in the ap-
plication of these basic skills to headache diagnosis and
treatment [12].
The development of practical management aids for
primary care therefore became an early objective of the
Global Campaign against Headache [17–19], a
programme of action for the benefit of people with
headache conducted by the UK-registered non-
governmental organization Lifting The Burden (LTB) in
official relations with WHO [20]. This manuscript pre-
sents one such aid, the Headache Under-Response to
Treatment (HURT) questionnaire; it describes its pur-
pose and its development, and summarises the studies
undertaking its psychometric evaluation and assessment
for clinical utility.
Objective
We believed that a simple outcome measure was insuffi-
cient. Whenever treatment of a patient is started, or
changed, follow-up should either ensure that treatment
is optimal or recognise that it is not and identify the
change(s) in treatment needed. Evaluation of outcome
should therefore be coupled with guidance to improve
outcome. While this was the instrument’s perceived pur-
pose, it is not so simple a purpose – resources, services
and expectations vary greatly between countries and
Table 1 Development group
Convener: TJ Steiner (UK)
Meeting in Geneva
RB Lipton (USA) (chairman), M Al Jumah (Saudi Arabia), B Eggleston
(Australia) (lay), M Fontebasso (UK), L Gardella (Argentina), RH Jensen
(Denmark), H Kettinen (Finland) (lay), MJA Láinez (Spain), FS Mennini
(Italy), M Peters (UK), L Prilipko (WHO), K Ravishankar (India), F Sakai
(Japan), N Sharma (India) (lay), TJ Steiner (UK), AD Tehindrazanarivelo
(Madagascar), D Valade (France), S-Y Yu (China)
Contributing remotely
W Stewart (USA), M Von Korff (USA)
Meeting in New York
RB Lipton (USA) (chairman), M Al Jumah (Saudi Arabia), S Broner (USA),
DC Buse (USA), ML Reed, (USA), D Serrano (USA), M Fontebasso (UK), FS
Mennini (Italy), TJ Steiner (UK)
Contributing remotely
RH Jensen (Denmark)
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ment met it [21]. No previously described instrument
had been shown to function for all important headache
disorders or across cultures, and no single instrument
covered the range of assessment and decision-making
necessary for successful headache management [21]. Few
made the key link between assessment and clinical ad-
vice, essential because, even in optimal circumstances,
outcomes are rarely perfect. Judgement may be needed
as to whether the outcome achieved in an individual pa-
tient is the best that the patient can reasonably expect.
For the non-specialist in particular, one question some-
times arising is: “What further effort, in hope of a better
outcome, is justified?” A second question, which may
follow, is “What is it that needs changing?”
The objective, therefore, was an instrument that would
both assess outcome and provide answers to these two
questions, offering guidance on appropriate actions to-
wards treatment optimisation. More specifically, we
aimed to create a short, simple-to-use management aid,
versatile yet reliable and sensitive, which met the pur-
pose described and three utility requirements:
1. in both primary and specialist care;
2. across the range of headache disorders of public-
health importance;
3. across countries and cultures, despite wide variation
in resources, services and expectations.
This objective would be reached through a
development process invoking expert consensus
followed by psychometric and clinical evaluations involv-
ing professional and lay representatives of all world
regions.
Methods
Development was a multi-stage process including item
development, item reduction using item-response theory
(IRT), psychometric testing and external validation, and
assessment of clinical utility.
For item development, LTB brought together an inter-
national expert consensus group (Table 1), with the
technical support of WHO. The members, from all six
world regions, included headache specialist health-care
professionals, primary-care physicians, lay patient advo-
cates and experts in health economics, psychometrics
and qualitative research. The group met first in April
2006 at WHO headquarters in Geneva and agreed the
domains that the instrument should address. After a lit-
erature review of existing instruments with related pur-
poses, a large item pool within these domains was
developed. In further discussions within the group, and
through consensus, initial item selection was followed by
a process of item reduction, refining the selection andlimiting the number of items to those considered most
apt (relevant and informative). These candidate items
were formulated into simple questions, with response
options based on the group’s expert knowledge and clin-
ical experience, and included in the emerging instru-
ment. A scoring system was constructed around them,
with guidance on interpretation. Accompanying clinical
advice, according to responses, was developed through
reference to authoritative treatment guidelines from
multiple countries coupled again with the group’s expert
input. A design process then built a first version
(“HURT-v1”) of the end-product as a 2-page document.
The Geneva group’s final task was to name the
instrument.
Psychometric evaluation (see below) was carried out
on HURT-v1. Informed by the results, a smaller group
met in New York City in October 2007 (Table 1), mak-
ing changes as necessary, again through consensus, and
generating the final version (“HURT-final”). Clinical
evaluations were performed on HURT-final.Evaluation
Two groups were involved in evaluation of HURT, one
in psychometric testing and the other in clinical assess-
ments (Table 2).Psychometric testing and validation
The American Migraine Prevalence and Prevention
(AMPP) Study [22] recruited from a panel constructed
and maintained by the survey company NFO, Inc.
(Ames, IA, USA) [23] to match the US population, ac-
cording to the national census, by age, gender, socioeco-
nomic status and region of the country. The AMPP
screening survey identified participants describing them-
selves as affected by “severe headache”, a term intended
preferentially to capture those with migraine and/or with
unmet needs for headache treatment. We included
Table 2 Evaluation groups
Psychometric evaluation
M Al Jumah (Saudi Arabia), A Al Khathami (Saudi Arabia),
A Al Owayed (Saudi Arabia), DC Buse (USA), A Jawhary (Saudi Arabia),
RH Jensen (Denmark), S Kojan (Saudi Arabia), RB Lipton (USA), EA
MacGregor (UK), ML Reed (USA), D Serrano (USA), CM Sollars (USA), TJ
Steiner (UK), H Tamim (Saudi Arabia), ML Westergaard
(Philippines/Denmark)
Clinical evaluation
M Al Jumah (Saudi Arabia), A Al Khathami (Saudi Arabia), A Al Owayed
(Saudi Arabia), F Antonaci (Italy), DC Buse (USA), A Jawhary
(Saudi Arabia), RH Jensen (Denmark), S Kojan (Saudi Arabia), RB Lipton
(USA), EA MacGregor (UK), TJ Steiner (UK), H Tamim (Saudi Arabia), C
Tassorelli (Italy), ML Westergaard (Philippines/Denmark)
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AMPP Study participants.
Ethics approval
The AMPP Study, with inclusion of HURT, was ap-
proved by the Albert Einstein College of Medicine Insti-
tutional Review Board. The mailings included
explanations of the study, and voluntary participation in
the surveys implied consent.
Sociodemographic variables
Recorded in these surveys were age, gender, weight and
height, all self-reported. Body-mass index (BMI) was cal-
culated from height and weight using the WHO stand-
ard formula. Data were also collected on average annual
household income, race and geographic region.
US mailing #1: Psychometric testing
HURT-v1, including all candidate items and response
options, was posted to a first sample (N = 2500) in sum-
mer, 2006. Enclosed in the mailing were question sets on
the sociodemographic variables and on headache fre-
quency, severity, associated symptoms and treatment.
The headache-related data were used to diagnose par-
ticipants with migraine, using the American Migraine
Study (AMS)/AMPP Study diagnostic module (demon-
strated to have 100% sensitivity and 82% specificity for
this diagnosis) [24]. Case-definition criteria for migraine
accorded with ICHD-II [25], except that a lifetime his-
tory of ≥5 attacks could not be ascertained from the
cross-sectional data. No significant changes have oc-
curred between ICHD-II [25] and ICHD-3-beta [10]
with regard to these criteria. Only participants with
headache on ≤14 days/month were included as migraine
cases (ie, episodic migraine) in this analysis.
Item analysis
Responses from these participants to HURT items 1–6
were included in a graded item-response model applied
to assess scale properties using SAS NLMIXED and to
identify an underlying latent variable. However, theHURT metrics for items 1–6 varied: four were count
items (with two based on 1 month’s recall and two based
on 3 months’ recall) and two were polytomous response
items. To simplify item analysis, we harmonized item re-
sponses, placing all on an identical metric. Count items
were converted to five-category polytomous items, with
severity values in the range 0–4 as follows:
1. 0 (very mild): 0 days in 1 month or 0 days in
3 months;
2. 1 (mild): 1–2 days in 1 month or 1–5 days in
3 months;
3. 2 (moderate): 3–5 days in 1 month or 6–10 days in
3 months;
4. 3 (severe): 6–15 days in 1 month or 11–20 days in
3 months;
5. 4 (very severe): ≥16 days in 1 month or ≥21 days in
3 months.
The original two polytomous response items were har-
monized so that higher-ordered response options were
also indicative of greater severity. Consequently, the
medication efficacy item was reverse-coded (0–4) to re-
flect increasing inefficacy, and the headache-control item
was reverse-coded (0–4) to reflect increasing lack of
control. Total and factor-specific scores could then be
computed as simple sums of the scale items.
An item-response model was fitted to these item
scores using a multinomial response-distribution. Item
parameters were estimated for the five response categor-
ies offered for each item. A confirmatory factor analysis
model was also employed where the original count items
loaded on the first factor and the original polytomous
items loaded on the second. The correlation between
the two factors was freely estimated.Performance across headache types
In the second mailing sample (described below), we
attempted to contrast HURT factor scores across
headache types to assess relative performance.US mailing #2: External validity
HURT-v1 was posted, in autumn 2006, to a different
sample (N = 2250), along with similar sociodemographic
and headache question sets. Included in this mailing
were multiple external validators: other instruments
used in headache management and themselves well-
validated as measures of headache-attributed impact,
treatment optimization, health-related QoL (HRQOL) or
comorbid depression. These are described in Table 3.
For purposes of correlation with these external valida-
tors, we used the total HURT scores derived during item
Table 3 Instruments used as external validators
Instrument Structure/purpose Scoring
Migraine Disability
Assessment (MIDAS)
scale [29]
5 items counting days of lost productivity
(complete or by > 50%) from paid or household
work and missed family, social or leisure activities
during the preceding 3 months
Sum of responses (the MIDAS score)
quantifies impact in days lost per 3 months
Headache Impact Test
(HIT-6) [30]
6 items assessing lost time at work, school or social
activities, pain severity, fatigue, frustration and difficulty
in concentration, each with 5 frequency response
options (never, rarely, sometimes, very often, always)
Response options scored 6, 8, 10, 11
and 13 respectively, with higher summed
scores (range 36–78) indicating
greater impact
Migraine Specific Quality
of Life (MSQ) questionnaire,
version 2.1 [32]
14 items assessing QoL in the preceding 4 weeks in 3
migraine-specific dimensions (role function-restrictive;
role function-preventive; emotional function), each
item having 6 Likert-type response options.
On a scale 0–100 (higher being better QoL)
through transformation involving 3 steps
PRIME-MD Patient Health
Questionnaire – depression
module (PHQ-9) [31]
Depressive symptoms over the preceding 2 weeks
assessed in the 9 domains of DSM-IV, each with 4
frequency response options (not at all, on several
days, on more than half of days, nearly every day)
Response options scored 0–3, with higher
summed scores (range 0–27) indicating more
severe depression
Migraine Prevention
Questionnaire (MPQ) [33]
5 items (regarding headache frequency, acute
medication use and headache-related impairment,
worry and anxiety) identify need for, and guide,
preventative pharmacological treatment of
migraine based on consensus guidelines
Responses summed into a total score, which
falls into one of 3 categories: preventative
treatment not indicated, should be
considered or should be offered
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correlations.Reliability
Two studies were undertaken to assess reliability, in very
different cultural and clinical settings. Both have been
published previously [26, 27], and are therefore only
summarised here.
HURT-final was completed twice by 159 consecutive
patients seeking non-urgent care in headache special-
ist centres in Denmark and United Kingdom (UK)
[26]. The instrument was first mailed to patients as
they joined the clinic waiting lists, before their initial
visits, and then given to them at these initial visits,
which were expected usually to take place about 1
month later.
For testing in Arabic-speaking patients in Saudi
Arabia, HURT was translated according to LTB’s transla-
tion protocol for hybrid documents [28]. Test-retest reli-
ability was assessed in 40 consecutive patients of four
primary-care centres, who completed HURT at two visits
4–6 weeks apart while receiving usual care [27].Ethics approval
In Denmark and UK, evaluation of HURT as an outcome
measure was considered a service-improvement project,
falling outside the scope of research ethics review [26].
Ethics approval was requested in Saudi Arabia, and
granted by the Institutional Review Board of National
Guard Health Affairs [27]. In both studies, information
was provided and all participants gave consent.Clinical testing
The first assessment of clinical utility, to demonstrate
that HURT was responsive to change induced by effect-
ive management, was conducted in headache specialist
centres in three European countries [26]. In Denmark
and UK, HURT was administered on a third occasion to
the same 159 consecutive patients when, in each case,
the treating specialist judged that the best possible out-
come had been achieved. In Italy, HURT was answered
by 42 patients at initial and final visits [26].
Clinical testing
The second assessment evaluated the Arabic version of
HURT in primary care in Saudi Arabia. The general
practitioners (GPs) in four centres were trained in head-
ache management, and the centres then randomized in
pairs to control (standard care) or intervention (care
guided by implementation of HURT). Responsiveness of
HURT to clinical change was assessed by comparing
base-line responses to HURT questions 1–6 with those
at follow up. Clinical utility was assessed by comparing
outcomes between control and intervention pairs after
3 months, using locally-developed 5-point verbal-rating
scales: patient-satisfaction scale (PSS) and doctor-
satisfaction scale (DSS) [27].
Ethics approval
In Denmark and UK, these studies again fell outside the
scope of research ethics review [26]. Ethics approvals
were obtained in Italy from the ethics review committee
of C Mondino Foundation, University of Pavia [26], and
in Saudi Arabia from the Institutional Review Board of
the King Abdullah International Medical Research
Table 4 Estimated factor scores for episodic migraine sub-
sample versus headache on ≥15 days/month sub-sample
Source DF Type III sum
of squares
Mean
square
F Pr > F
Migraine 1 0.5951 0.5951 0.78 0.3763
Effect 1 0.1050 0.1050 0.14 0.7101
Migraine*Effect 1 0.1579 0.1579 0.21 0.6486
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provided and all participants gave consent.
Results
The Geneva meeting identified the following as essential
domains: headache frequency, disability, medication use
and effect, patients’ perceptions of headache “control”
and their understanding of their diagnoses. The group
developed an 8-item self-administered questionnaire
addressing these. Responses were either numerated in
days over a one- or three-month recall-period or
selected from Likert options. In either case, responses
were graded into an area of “no concern” or one of three
flagged areas indicating increasingly important treatment
deficiencies; clinical advice was provided for each of the
latter.
The design process constructed the questionnaire,
with responses, interpretation and advice, into the form
shown (Additional file 1).
After the psychometric evaluations, and informed by
them, the New York meeting made only minimal
changes to generate HURT-final.
Psychometric evaluation
Psychometric testing
In the assessment of scale properties, valid returns came
from 1691 (68%) respondents to the first US mailing. A
large majority (1362; 81%) met ICHD-II criteria for mi-
graine [25]. IRT revealed a two-factor model: 1) head-
ache frequency, disability and medication use; and 2)
medication efficacy and headache control items. Total
and sub-factor scores correlated strongly (Spearman co-
efficient r = 0.49–0.86).
Performance across headache types
In the second US mailing sample, which, like the first,
were self-selecting for “severe” headache, sub-sample
sizes for headache types other than episodic migraine
were very low (≤100): 73 cases met criteria for episodic
TTH (ETTH); 100 had headache on ≥15 days/month,
with ten of these diagnosed as chronic migraine. Several
simplifying modifications were attempted in order to
contrast other headache types with episodic migraine,
but all models failed in the face of these small samples
and insufficient information. Furthermore, respondents
with headache on ≥15 days/month inevitably reported a
constant (maximal) value on HURT item 1 (headache
days/month). As a last resort, fitting the item-response
model separately to the episodic migraine sub-sample
and the headache on ≥15 days/month sub-sample (the
only other for which the model contrast was estimable),
we compared the estimated factor scores for these two
groups in an ANOVA (Table 4). No significant differ-
ences were observed in factor scores for the two factors,suggesting no meaningful difference in the performance
of HURT between these headache types.External validity
Valid returns to the second mailing were received from
1734 (69%) respondents, of whom 1391 (80%) met
ICHD-II criteria for migraine [25]. Summed HURT
scores correlated in the expected directions with the
other measures. Correlations were positive with both the
MIDAS questionnaire (r = 0.69) and HIT-6 (r = 0.49),
instruments that are strongly influenced by disability
[29, 30], and with PHQ-9 (r = 0.34), a measure of depres-
sion [31]. Correlations were negative with MSQ version
2.1, a migraine-specific QoL instrument [32], so that
higher HURT scores were associated with poorer QoL
(restrictive subscale: r = − 0.53; preventative subscale: r =
− 0.58; emotional subscale: r = − 0.51). HURT scores cor-
related most strongly, and positively, with MPQ (r =
0.86), an instrument indicating need for preventative
pharmacological treatment of migraine [33]. These cor-
relations suggested that, while the instruments shared
some variance, they nonetheless captured unique
constructs.Reliability
Test-retest reliability in specialist care in Denmark and
UK was fair to low (κ = 0.38–0.62; r = 0.49–0.76) [26]. It
should be noted that, while the interval between first
and second applications of HURT was intended in the
study design to be about 1 month, subsequent review of
the Danish records revealed a range between 1 day and
9 months (median 1.7 months). The longer-than-
planned intervals were caused in part by the centre’s ex-
tending waiting time but also in part by patients who
changed appointment dates – sometimes introducing
long delays. Internal consistency reliability on the other
hand was very good (Cronbach’s α = 0.85) [26]. In Saudi
Arabian primary care, intra-class correlation coefficients
were 0.66–0.78 (all p ≤ 0.001) for questions 1–4 and
0.90–0.93 for questions 5–7 (all p < 0.0001) [27]. For the
dichotomous response to question 8, κ = 1 (p < 0.0001).
Internal consistency reliability was good (Cronbach’s α =
0.74) [27].
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In specialist-care utility evaluation in 201 patients in Eur-
ope, with HURT administered at the start and end of treat-
ment, good outcomes were judged to have been achieved
in 155 (77%) [26]. HURT reflected these in significant dif-
ferences between recorded responses at base line and post-
intervention (p < 0.01), indicating responsiveness of the in-
strument to change. Analyses of paired responses (before
and after treatment) found seven of the eight HURT items
indicating improvements (p < 0.001). No evident improve-
ment in patients’ concerns about side-effects of medication
was indicated by item 7 (p = 0.18) [26].
In 342 patients in Saudi Arabian primary care, HURT
signalled clinical improvement over 3 months through
statistically significant reductions (p < 0.0001) in re-
sponses to each of questions 1–6 [27]. HURT also distin-
guished clearly between patients with good or poor
outcomes, with questions 1–4 each (p < 0.0001) indicat-
ing improvement in those reporting satisfaction (positive
PSS scores) and worsening (or no improvement) in those
reporting dissatisfaction (negative PSS scores) [27].
There was a trend (p = 0.06) towards greater patient-
satisfaction among those treated with guidance from
HURT (n = 207) than among controls (n = 135). There
was a slight opposite trend in doctor-satisfaction [27].
Discussion
HURT is a consensus-developed 8-item self-administered
questionnaire addressing headache frequency, disability,
medication use and effect, patients’ perceptions of head-
ache “control” and their understanding of their diagnoses.
Its scope is unique among outcome measures.
In the evaluations, HURT proved to be a psychomet-
rically sound instrument for monitoring headache treat-
ment, with, importantly, scale properties apparently
stable across headache disorders. While test-retest reli-
ability in specialist care was assessed as fair to low, this
was, very probably, because headache in this setting, and
prior to start of management, was unstable over time.
Although this was not intended, intervals of up to
9 months between the two applications of HURT
allowed the possibility of real change in many patients.
In the very different setting of Saudi Arabian primary
care, reliability was good for questions 5 to 7, to which
responses expressed beliefs or perceptions at the time of
testing. It was less good for questions 1 to 4, which re-
quired recall of past events over 1 to 3 months and
which, again, were subject to real changes in the fre-
quencies of events potentially occurring over the test-
retest period. It should be noted also that, unlike in
Europe, patients in Saudi Arabia did receive an interven-
tion (albeit only standard care) between the two admin-
istrations of HURT. The two settings were, therefore,
not comparable for testing reliability (it was notintended that they should be). In USA, summed scores
correlated well and in the expected directions with ex-
ternal validation measures.
The literature search yielded a multiplicity of psycho-
metrically robust instruments available to support the
several key steps in comprehensive care of headache dis-
orders [21]. These instruments can be used to aid the
diagnosis of primary headache disorders; the exclusion
of secondary headaches; the assessment of headache
symptoms and their severity, headache-attributed dis-
ability, burden and impact (both ictal and interictal); the
recognition and assessment of comorbidities, and of psy-
chological factors shown to predict adherence to treat-
ment and outcomes; outcome measurement including
patients’ satisfaction; and treatment planning, monitor-
ing and optimization for both acute and preventative
pharmacological therapies. Many have particular
strengths. MIDAS in particular, although it measures
headache-attributed lost time rather than disability [34],
is scored in meaningful units, is easy to use, has demon-
strated reliability and validity, predicts treatment needs,
has been extensively used in clinical practice in many
countries and is sensitive to change, at least in severely-
affected patients. However, no single instrument other
than HURT combines so many of these aspects of care,
and, especially, few instruments link assessment to clin-
ical advice or suggested actions [21]. Thus, they do not
serve non-headache experts well, especially health-care
providers in primary care.
The HURT questionnaire was created to fill this gap
and it appears to have the capability of doing so.
In Europe, HURT showed utility in specialist care as
an outcome measure across headache disorders. In this
setting, where many patients are partially or wholly re-
fractory even to best care, HURT can be used to define
and explain treatment goals. In addition, it can promote
self-efficacy and knowledge about headache. In Saudi
Arabian primary care, where no other Arabic instru-
ments were available as standards for comparison,
HURT was reliable and responsive to clinical change
and therefore it has clinical utility in Arabic-speaking pa-
tients. One explanation of the apparent discord between
doctors’ and patients’ satisfaction in Saudi Arabia is that
the instrument worked as it should – improving care
(perceived by patients) while revealing deficiencies in
care and need for improvement to the physicians.
Conclusions
The HURT questionnaire has demonstrated validity and
clinical utility, and is currently available for clinical use
and research purposes in English and Arabic. Some
other translations are known to exist, and future work
may include use and evaluation in other countries and
cultures.
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